Core Insights - Earth Science Tech, Inc. (ETST) has qualified for and been listed on the newly launched OTCID tier of the OTC Markets, reflecting its commitment to enhanced disclosure and compliance standards [1][2] - The CEO, Giorgio R. Saumat, highlighted the company's significant turnaround over the past two years and expressed optimism about future growth and increased investor confidence due to this new designation [3] Company Overview - ETST operates as a strategic holding company focused on acquiring and optimizing high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through various subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][10] Subsidiary Highlights - **RxCompoundStore.com**: A fully licensed compounding pharmacy serving multiple states and actively pursuing licensure in remaining U.S. states [5] - **Mister Meds**: A compounding pharmacy in Texas that received full licensure in March 2025 and is expanding its service area [6] - **Peaks Curative**: A telemedicine platform offering consultations for compounded medications and recently expanded into the veterinary market [7] - **Las Villas Health Care**: A healthcare facility focused on the Spanish-speaking community, providing specialized health services [8] - **Avenvi**: A diversified real estate company managing development and financing activities, overseeing a $5 million share repurchase program [10] - **Earth Science Foundation**: A nonprofit organization supporting individuals with financial needs for prescription costs [11]

Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, today shares its financial results for the year ended March 31, 2025. For the fiscal year ended March 31, 2025, the Company reported the following results: Cash: $1,473,228, compared to $697,721 as of March 31, 2024—an increase of $775,507, representing a 1 ...

Hims & Hers Health shares rocketed higher over the last year, rewarding investors. When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services. What does Oscar Health do, and why might it draw comparisons to Hims & Hers? When it comes to accessing patient care, consumers have a couple of optio ...

Concentra Group Holdings Parent (CON) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants Keith Newton - CEOMatthew DiCanio - President & CFOBenjamin Rossi - Equity Research AssociateBen Hendrix - Vice PresidentEdward Kressler - Managing Director Conference Call Participants Jamie Perse - AnalystJoanna Gajuk - Equity Research AnalystStephen Baxter - Senior Equity Research AnalystJustin Bowers - Analyst Operator Good morning and thank you for joining us today for Concentra Group Holdings Pare ...